Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period
NCT ID: NCT05712759
Last Updated: 2025-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2025-03-09
2025-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
HAI is transmitted via respiratory droplets and by hand contacts. The spread is facilitated by Health Care Professionals (HCPs), patients and visitors.
Prevention and control of HAI is of upmost importance to preserve patient safety and limit the related economic costs. While vaccination of HCPs has been shown to contribute to the reduction of HAI, less is known on the impact of patient vaccination on the risk of HAI during hospitalization.
The aim of this study is to describe the hospital-acquired influenza in a french university hospital.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multiplex PCR for Severe Respiratory Infections During the COVID-19 Pandemic
NCT06349707
Artificial Intelligence for Respiratory Infections SEverity Prediction
NCT07047768
Study of Symptoms Linked to Covid-19 in Residents and Professionals in EHPAD, Associated With a Dual Diagnostic Approach by PCR and Serology: a Cohort in Île-de-France.
NCT04677283
Haemophilus Influenzae Pneumonia in Adults
NCT06517277
Lung Bacteriobiota and Influenza Mortality
NCT04131296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Influenza-like illness group
Each patient who present ILI (influenza-like illness) at admission or during hospitalization and who have had a nasopharyngeal swab taken as part of their care for the purpose of diagnosing influenza by Polymerase Chain reaction (PCR) testing.
ILI is defined by fever \> 37,8°C or/and cough or sore throat.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fever greater than 37.8°C in the absence of antipyretics; And/or
* Cough or pharyngeal pain.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL22_1064
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.